Filing Details
- Accession Number:
- 0001062993-25-011400
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-11 16:20:06
- Reporting Period:
- 2025-06-09
- Filing Date:
- 2025-06-11
- Accepted Time:
- 2025-06-11 16:20:06
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2055523 | E. Amy Herr | 614 Mckinley Place Ne Minneapolis MN 55413 | Yes | No | No | No |
Transaction Summary
| Sold: | 1,280 shares | Avg. Price: $49.77 | Total Value: $63,704.83 |
| Number of Shares After Transactions: | 1,976 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-09 | 1,280 | $44.33 | 3,256 | No | 4 | M | Indirect | By significant other |
| Common Stock | Disposition | 2025-06-09 | 1,280 | $49.77 | 1,976 | No | 4 | S | Indirect | By significant other |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Indirect | By significant other |
| No | 4 | S | Indirect | By significant other |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-09 | 1,280 | $0.00 | 1,280 | $44.33 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-08-08 | No | 4 | M | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,040 | Direct |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | $72.05 | 2035-02-03 | 2,415 | 2,415 | Direct | |
| Common Stock | Stock Option (Right to Buy) | $47.60 | 2026-08-07 | 6,636 | 6,636 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $66.97 | 2027-08-05 | 4,472 | 4,472 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $120.46 | 2028-08-06 | 2,076 | 2,076 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $94.52 | 2029-08-15 | 2,104 | 2,104 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $84.61 | 2030-08-15 | 1,084 | 1,084 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $74.91 | 2034-08-15 | 1,468 | 1,468 | Indirect | |
| Common Stock | Stock Option (Right to Buy) | $72.05 | 2035-02-03 | 344 | 344 | Indirect | |
| Common Stock | Restricted Stock Units | $0.00 | 237 | 237 | Indirect | ||
| Common Stock | Restricted Stock Units | $0.00 | 480 | 480 | Indirect | ||
| Common Stock | Restricted Stock Units | $0.00 | 115 | 115 | Indirect |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2035-02-03 | 2,415 | 2,415 | Direct |
| 2026-08-07 | 6,636 | 6,636 | Indirect |
| 2027-08-05 | 4,472 | 4,472 | Indirect |
| 2028-08-06 | 2,076 | 2,076 | Indirect |
| 2029-08-15 | 2,104 | 2,104 | Indirect |
| 2030-08-15 | 1,084 | 1,084 | Indirect |
| 2034-08-15 | 1,468 | 1,468 | Indirect |
| 2035-02-03 | 344 | 344 | Indirect |
| 237 | 237 | Indirect | |
| 480 | 480 | Indirect | |
| 115 | 115 | Indirect |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 49.7471 to 49.8100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vests on the earlier of the one-year anniversary of the grant date or the date of Bio-Techne's annual meeting of shareholders.
- Fully vested.
- 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and 516 shares vest on 8/6/2024.
- 528 shares vest on 8/15/2023 and 8/15/2025; 524 shares vest on 8/15/2024 and 8/15/2026.
- 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026.
- 160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.
- 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.
Billionaire Hedge Funds
